A follow-up of Savino’s 2010 study to investigate if the administration of L. reuteri DSM 17938 in infantile colic may affect prevalence of atopic disorders (cow’s milk allergy and atopic dermatitis), asthma and migraine at the age of five, and effects on growth. The original study was a double blind and placebo-controlled one, which randomised 50 colicky infants at baseline, whereof 46 were analysed for results. Twenty-five (25) in the L. reuteri group and 23 in the placebo group were analysed in this follow-up study.
The prevalence of atopic disorders was significantly lower in the L. reuteri group compared to placebo, with an odds ratio of 0.16 (95% CI: 0.03-0.88).
Asthma was absent in both groups, while there was one case of migraine in the placebo group. Growth was equal in the two groups, measured as BMI Z-score.
Conclusion: The results provide preliminary evidence of clinical efficacy of L. reuteri DSM 17938 supplementation in the first months of life on atopic disorders (cow’s milk allergy and atopic dermatitis) at five years of age. No safety issues were identified.
The aim of this study was to evaluate the effect on oral health, at age 9 years, of daily oral supplementation with the probiotic Lactobacillus reuteri, strain ATCC 55730, to mothers during the last month of gestation and to children through the first year of life.
The study was a single-blind, placebo- controlled, multicenter trial involving 113 children: 60 in the probiotic and 53 in the placebo group. The subjects underwent clinical and radiographic examination of the primary dentition and carious lesions, plaque and gingivitis were recorded. Saliva and plaque were sampled for determination of mutans streptococci (MS) and lactobacilli (LB) in saliva and plaque as well as salivary secretory IgA (SIgA).
49 (82%) children in the probiotic group and 31 (58%) in the placebo group were caries-free (p < 0.01). The prevalence of approximal caries lesions was lower in the probiotic group (0.67 ± 1.61 vs. 1.53 ± 2.64; p < 0.05) and there were fewer sites with gingivitis compared to the placebo group (p < 0.05). There were no significant differences between the groups with respect to frequency of toothbrushing, plaque and dietary habits, but to intake of fluoride supplements (p < 0.05). There were no intergroup differences with respect to L. reuteri, MS, LB or SIgA in saliva.
Within the limitation of this study it seems that daily supplementation with L. reuteri from birth and during the first year of life is associated with reduced caries prevalence and gingivitis score in the primary dentition at 9 years of age.
In a study on prevention of allergy in newborns, L. reuteri ATCC 55730 reduced the incidence of IgE-associated allergic disease in infancy. This treatment might therefore also reduce the risk of asthma and allergic rhino‑conjunctivitis in school age, which this follow-up study set out to investigate. It also evaluated whether this supplementation was associated with any long-term side effects. The age at follow-up was 7y.
In the 2007 double-blind, and placebo controlled trial, 232 infants were randomised and 188 completed. 184 children took part in the follow-up, whereof 94 in the L. reuteri group and 90 in placebo group.
For the allergic disease outcomes there were no differences between groups: The prevalence of asthma was 15% in the L. reuteri vs. 16% in placebo group; allergic rhino conjunctivitis: 27% vs. 20%; eczema: 21% vs. 19%; skin prick test reactivity: 29% vs. 26%. Growth indices and gastrointestinal symptoms were similar in the two groups. No severe adverse events were reported.
Conclusion: The effect of L. reuteri on sensitization and IgE-associated eczema in infancy did not lead to a lower prevalence of respiratory allergic disease in school age. Thus, the effect of L. reuteri on the immune system seems to be transient. Administration of L. reuteri during the last weeks of gestation and in infancy was not associated with any long-term side effects.
A prospective, double blind, randomised, placebo-controlled trial with the objective to prevent eczema and sensitization in infants born in families with allergic disease by oral supplementation with the probiotic Lactobacillus reuteri.
The study included 232 families, of whom 188 completed the study. The mothers received Lactobacillus reuteri ATCC 55730 (1 × 10^8 colony forming units) daily from gestational week 36 until delivery. Their babies then continued with the same product and dose from birth until 12 months of age and were followed up for another year.
Primary outcome was allergic disease, with or without positive skin prick test or circulating IgE to food allergens (tests indicating that sensitization has taken place). At two years of age the incidence of eczema was eczema during the second year, 8% versus 20% (P=0.02). Skin prick test reactivity was also less common in the Lactobacillus reuteri group compared to the placebo group, significantly so for infants with mothers with allergies, 14% versus 31% (P =0.02). Wheeze and other potentially allergic diseases were not affected.
Conclusion: Lactobacillus reuteri had no preventive effect on total incidence of infant eczema. At 2 years of age, however, the Lactobacillus reuteri supplemented infants had less IgE-associated eczema (i.e. eczema with hyperreactivity to allergy-causing substances such as egg and milk) and therefore possibly run a reduced risk to develop later respiratory allergic disease.